NCT07925983
A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Maximum Serum Concentration (Cmax) of trosunilimab
Timeframe: Up to 7 Days
Time to Cmax (Tmax) of trosunilimab
Timeframe: Up to 7 Days
Concentration at Week 4 (Cwk4) of trosunilimab
Timeframe: Week 4
Area under the serum concentration-time curve from Week 0 to 4 (AUC0-4wk) of trosunilimab
Timeframe: Weeks 0 to 4
Number of Participants Experiencing Adverse Events
Timeframe: Up to 140 Days
Arms and interventions
Arm 1: Trosunilimab IVActive comparator
Participants will receive an intravenous (IV) trosunilimab dose
Arm 2: Trosunilimab SCActive comparator
Participants will receive subcutaneous (SC) injection doses of trosunilimab
Drugs: Trosunilimab
Sites
1 site in 1 country
- Acpru /Id# 286224Grayslake, Illinois, United States